All In Biotech

Drug Trial Radar · NCT06072781

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Mar 18, 2024

Primary completion

Oct 15, 2028

Study completion Feb 9, 2031

Sponsor

Lead sponsor
Verastem, Inc.Industry
Sponsor type
Industry
Collaborators
GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT); Australia New Zealand Gynaecological Oncology Group; Korean Gynecologic Oncology Group
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Conditions

  • Low Grade Serous Ovarian Cancer

Interventions

  • avutometinibDrug

    Avutometinib: administered orally

  • DefactinibDrug

    Defactinib: administered orally

  • Pegylated liposomal doxorubicinDrug

    administered intravenously

  • PaclitaxelDrug

    administered intravenously

  • LetrozoleDrug

    administered orally

  • AnastrozoleDrug

    administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) per blinded independent central review (BICR)Time frame: Up to 24 months

Locations

105 sites in 16 countries. Site status is shown where the registry gives one.

  • HonorHealth

    Phoenix, Arizona · Recruiting

  • University of Arkansas

    Little Rock, Arkansas · Recruiting

  • UCLA Health

    Los Angeles, California · Recruiting

  • UC Davis

    Sacramento, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Active not recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialists - South

    Fort Myers, Florida · Recruiting

  • Mount Sinai

    Miami Beach, Florida · Recruiting

  • AdventHealth

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Florida Cancer Specialists Research East

    West Palm Beach, Florida · Recruiting

  • Winship Cancer Institute at Emory University

    Atlanta, Georgia · Recruiting

  • NorthShore University HealthSystem

    Evanston, Illinois · Recruiting

  • Louisiana State University

    New Orleans, Louisiana · Recruiting

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland · Recruiting

  • Karmanos Cancer Center

    Detroit, Michigan · Recruiting

  • Minnesota Oncology Hematology

    Minneapolis, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Active not recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Atrium Health

    Charlotte, North Carolina · Recruiting

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Ohio State

    Hilliard, Ohio · Recruiting

  • University of Oklahoma Medical Center

    Oklahoma City, Oklahoma · Recruiting

  • Willamette Valley Cancer Institute

    Eugene, Oregon · Recruiting

  • Northwest Cancer Specialists

    Portland, Oregon · Recruiting

  • Asplundh Cancer Pavilion | Jefferson Health

    Philadelphia, Pennsylvania · Recruiting

  • Allegheny Health Network

    Pittsburgh, Pennsylvania · Recruiting

  • Texas Oncology Central

    Austin, Texas · Recruiting

  • Texas Oncology-Fort Worth Cancer Center

    Fort Worth, Texas · Recruiting

  • Houston Methodist

    Houston, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Texas Oncology

    San Antonio, Texas · Recruiting

  • Texas Oncology

    The Woodlands, Texas · Recruiting

  • Texas Oncology

    Tyler, Texas · Recruiting

  • Intermountain Medical Center

    Murray, Utah · Recruiting

  • University of Virginia Health System

    Charlottesville, Virginia · Recruiting

  • Virginia Cancer Specialists, PC

    Gainesville, Virginia · Recruiting

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia · Recruiting

  • Icon Cancer Centre Wesley

    Auchenflower, Queensland, Australia · Recruiting

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.